Study #2022-0067
Augment-102: a phase 1, open-label, dose-escalation study to evaluate safety, tolerability and preliminary anti-leukemic activity of SNDX-5613 in combination with chemotherapy in patients with relapsed/refractory leukemias harboring a KMT2A/MLL gene rearrangement or nucleophosmin 1 mutation (mnpm1)
MD Anderson Study Status
Not Accepting
Treatment Agent
Revumenib, Chemotherapy Regimen 1, Chemotherapy Regimen 2
Description
The purpose of this study is to determine the safety and tolerability of revumenib when given in combination with 2 different chemotherapy regimens in participants with relapsed/refractory acute leukemias harboring KMT2A rearrangement, KMT2A amplification, NPM1c, or NUP98r.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Relapsed/Refractory Leukemias, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Mixed Phenotype Acute Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia
Study phase:
Phase I
Physician name:
Ghayas Issa
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.